BioCardia (BCDA) Capital Expenditures Growth (3y) (2020 - 2026)
Powered by 
Analysis
BioCardia (BCDA) Capital Expenditures Growth (3y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 82.83% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -9.77% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -7.20% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | -68.59% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | -19.62% |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -33.06% |
| Dec 31, 2025 | 44.22% |
| Jun 30, 2025 | -65.80% |
| Dec 31, 2024 | -71.00% |
| Sep 30, 2024 | -53.58% |
| Jun 30, 2024 | -52.50% |
| Jun 30, 2023 | -20.63% |
| Mar 31, 2023 | 25.99% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | -11.21% |
| Jun 30, 2022 | -28.71% |
| Mar 31, 2022 | -19.21% |
| Dec 31, 2021 | 39.82% |
| Sep 30, 2021 | 58.74% |
| Jun 30, 2021 | -11.94% |
| Mar 31, 2021 | 75.44% |
| Sep 30, 2020 | 48.67% |
| Jun 30, 2020 | -51.93% |
| Mar 31, 2020 | -57.25% |